A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
NCT07719608
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant migraine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Resistant Migraine
- Chronic Migraine Headache
- Headache (Migraine)
- Headache, Cluster
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 to 84 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Salvia BioElectronics
- Last updated on ClinicalTrials.gov
- August 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Vista Clinical Research · Newnan, GA
Maryland · 1
- MedStar Health Research Institute · Olney, MD
North Carolina · 1
- Queen City Clinical Research, PLLC · Charlotte, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.